Zealand’s obesity drug shouldn’t disrupt Novo Nordisk-Eli Lilly leadership: Mizuho’s Jared Holz

February 26, 2024
Zealand’s obesity drug shouldn’t disrupt Novo Nordisk-Eli Lilly leadership: Mizuho’s Jared HolzZealand’s obesity drug shouldn’t disrupt Novo Nordisk-Eli Lilly leadership: Mizuho’s Jared Holz

Jared Holz, Mizuho Americas, joins ‘Fast Money’ to talk obesity drugmakers after a new study out of Zealand Pharma analyzed the impact of GLP-1s on liver disease.

Share This

Latest Mizuho News

See all news
Biopharma thesis starting to move away from obesity drugs, says Mizuho’s Jared Holz

Biopharma thesis starting to move away from obesity drugs, says Mizuho’s Jared Holz

March 20, 2026
Mizuho Securities Analyst on Latest with Oil and Gas Amid Middle East Conflict

Mizuho Securities Analyst on Latest with Oil and Gas Amid Middle East Conflict

March 13, 2026
Mizuho awarded Coalition Greenwich 2026 Best Bank distinctions in the U.S.

Mizuho awarded Coalition Greenwich 2026 Best Bank distinctions in the U.S.

March 17, 2026

Mizuho news from around the globe

 Mizuho Global News
back-to-top-blue